SLC5A4 and cystic fibrosis: When combined with the potentiator, IVA, they partially rectify CFTR function and alter CFTR-ENaC coupling, which results in the inhibition of the elevated amiloride-sensitive sodium transport that is characteristic of CF (Cholon et al., 2014; Pranke et al., 2017).